Synfacts, Table of Contents Synfacts 2024; 20(07): 0760DOI: 10.1055/s-0043-1763969 Innovative Drug Discovery and Development LXRβ-Selective Tricyclic Agonist Developed with New [4σ+4π] and [4σ+4π–1] Cycloaddition Strategy Authors Contributor(s): Dirk Trauner Joseph A. Flores Recommend Article Abstract Buy Article(opens in new window)Key words Key wordstype-I cycloaddition - [4σ+4π] cycloaddition - benzocyclobutenone - LXR agonist Full Text
